发明公开
EP1554309A2 ANTIBODIES AND CYCLIC PEPTIDES WHICH BIND CEA (CARCINOEMBRYONIC ANTIGEN) AND THEIR USE AS CANCER THERAPEUTICS
审中-公开
抗体和环肽的CEA（“癌胚抗原”）结合位及其作为癌症治疗剂
- 专利标题： ANTIBODIES AND CYCLIC PEPTIDES WHICH BIND CEA (CARCINOEMBRYONIC ANTIGEN) AND THEIR USE AS CANCER THERAPEUTICS
- 专利标题（中）： 抗体和环肽的CEA（“癌胚抗原”）结合位及其作为癌症治疗剂
-
申请号： EP03769082.3申请日： 2003-10-03
-
公开(公告)号： EP1554309A2公开(公告)日： 2005-07-20
- 发明人: STANNERS, Clifford, P. , ILANTZIS, Christian
- 申请人： McGILL UNIVERSITY
- 申请人地址： 845 Sherbrooke Street West Montreal,Québec H3A 2T5 CA
- 专利权人： McGILL UNIVERSITY
- 当前专利权人： McGILL UNIVERSITY
- 当前专利权人地址： 845 Sherbrooke Street West Montreal,Québec H3A 2T5 CA
- 代理机构： Neuefeind, Regina
- 优先权： US415520P 20021003
- 国际公布： WO2004031238 20040415
- 主分类号： C07K14/705
- IPC分类号： C07K14/705 ; C07K16/30 ; C07K16/28
摘要：
The present invention relates to differentiation and tumorigenicity. The present invention more particularly relates to ligands which target CEA and CEACAM6 such that the adhesion, differentiation-Inhibitory activities and tumorigenic effects of Ig superfamily members, CEA and CEACAM6, can be reduced or blocked. More particularly, the present invention relates to CEA-binding agents which reverse CEA-mediated tumorigenic effects by declustering CEA and CEACAM6. In one embodiment the invention relates to methods of reducing, preventing or reversing a CEA-mediated tumorigenic effect comprising a use of a CEA-mediated tumorigenic effect reducing CEA-declustering agent. In one embodiment, the invention relates to compositions and use thereof for reversing CEA-mediated tumorigenic effects on human cancer cells and uses thereof. In particular, the application relates to a monovalent CEA binding agent which interfereswith a CEA interaction responsible for a CEA-mediated tumorigenic effects, thereby minimizing or reversing same.
信息查询
